Premium
Cell of origin fails to predict survival in patients with diffuse large B‐cell lymphoma treated with autologous hematopoietic stem cell transplantation
Author(s) -
Gu Keni,
Weisenburger Dennis D,
Fu Kai,
Chan Wing C,
Greiner Timothy C,
Aoun Patricia,
Smith Lynette M,
Bast Martin,
Liu Zhongfen,
Bociek R. Gregory,
Bierman Philip J,
Armitage James O,
Vose Julie M
Publication year - 2012
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.1017
Subject(s) - lymphoma , hematopoietic cell , hematopoietic stem cell transplantation , cell , stem cell , transplantation , medicine , haematopoiesis , diffuse large b cell lymphoma , pathology , cancer research , immunology , biology , microbiology and biotechnology , genetics
Diffuse large B‐cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B‐cell (GCB) and the non‐GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantation (AHSCT). We identified 62 patients with DLBCL who either had an initial complete remission (17 patients) or received salvage chemotherapy for relapsed or refractory disease (45 patients), followed by AHSCT. Tissue microarrays were immunostained with monoclonal antibodies against GCET1, CD10, BCL6, MUM1, FOXP1 and LMO2. Using the Hans algorithm, we classified 50% of the cases as GCB type, whereas the Choi algorithm classified 58% as GCB type and LMO2 was positive in 69%. However, no significant differences were found in the 5‐year overall or event‐free survivals using any of these approaches. In conclusion, cell of origin fails to predict survival of DLBCL patients treated with AHSCT. Copyright © 2011 John Wiley & Sons, Ltd.